




BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance 






















Supplementary Figure 1. Additional characterization of SNU-251 cells. 
(a) MDA-MB-231, MDA-MB-436 and SNU-251 cells were maintained in the presence of 1 µM rucaparib and 
collected for analyses every 24 hours. Cells were stained with propidium iodide and cell cycle profiles were 
determined by flow cytometry. Representative cell cycle profiles are shown, n=3 biological replicates. (b) 
MDA-MB-231, MDA-MB-436, SNU-251 parental (P), SNU-251 rucaparib resistant (RR) cells were seeded at 
decreasing densities in the presence of either vehicle or 50 ng/ml cisplatin or 2 Gy IR and colonies counted 2-
 3 
weeks post-seeding. Cell survival was expressed as a percentage of vehicle-treated cells. Data are the 
mean ± S.D. of n = 3 biological replicates. Statistical significance was assessed by unpaired, two-tailed t-tests. 
 *** p < 0.001, compared to MDA-MB-231. Representative plates are shown for data presented in Fig. 1c. (c) 
Sanger sequencing was carried out and electropherograms are presented showing retention of the BRCA1 
c.5445G>A mutation in SNU-251 and SNU-251-RR cells. BROCA sequencing was also performed, which covers 
the entire BRCA1 gene, and confirmed the absence of secondary reversion mutations in SNU-251-RR cells, see 
Supplementary Data 2 file for BROCA sequencing results. (d) 53BP1 and PARP1 expression were assessed by 
Western blotting. (e) MDA-MB-231 and SNU-251-RR cells were treated with scrambled (Sc), BRCA1 exon 11 
(E11) or BRCA1-D11q (11q) targeting siRNA and lysates collected for Western blotting. (f) MDA-MB-231, MDA-
MB-436-RR1 that were previously characterized to be dependent on HSP90 for folding1, and SNU-251-RR cells 
were treated with cycloheximide (CHX) for 0, 6, or 12 hours and lysates collected for Western blotting. In line 
with our previous work, inhibition of translation with CHX treatment did not impact HSP90-associated 
stabilized BRCA1 protein levels in MDA-MB-436 RR-1 cells1. (g) Cell lines described in f were treated with 
HSP90 specific inhibitor AT13387 (500 nM) for 48 hours and lysates collected for Western blotting. 
Interestingly, all BRCA1 isoforms, including full-length/wild-type, showed HSP90 dependency. (h) Sanger 
sequencing was performed on DNA from SNU-251-RR cells. Electropherogram compared to the hg38 
reference sequence shows the BRCA1 exon 15 intron 15 junction. No splice site mutations were present in 
SNU-251 or SNU-251-RR cells. 
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Supplementary Figure 2. WGS analyses of BRCA1 in SNU-251-RR cells. 
Above, Integrative Genomics Viewer (IGV) snapshot of WGS reads spanning NBR2 and BRCA1 genes on 
chromosome 17 detected in SNU-251-RR cells. Red box indicates the amplified 5’ and 3’ termini. Below, the 5’ 
and 3’ ends of the amplified BRCA1 region is magnified to show individual reads. The amplified region starts 
(5’) in NBR2 intron 1 (Chr17: 41281775) and ends (3’) in BRCA1 intron 15 (Chr17: 4122418). Gray reads map 
100% with hg19. Teal and blue flagged reads indicate single reads that map to both the sequence where the 
read is aligned, as well as additional sequences at alternative genomic locations. Red arrows and green arrows 





 Supplementary Figure 3. Assessment of HR in SNU-251 cells. 
(a) Nuclear (n) and cytoplasmic (c) extracts were generated and BRCA1 protein expression measured. 53BP1 
and tubulin were measured as controls for nuclear and cytoplasmic separations, respectively. Of note, BRCT 
domain mutations have previously been shown to result in the protein being located in the cytoplasmic 
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compartment. There are no known localization signals in the BRCT domain; rather, BRCT mutations reduce 
nuclear import due to altered protein folding and degradation by cytoplasmic proteasome complexes. We and 
others have previously shown more extensive C-terminal deletions, occurring prior to the BRCT repeats, 
restores nuclear BRCA1 expression, as proteins folded correctly2,3. Of note exon 11 contains nuclear 
localization signals are retained in BRCA1-BRCTless proteins3,4. (b) Representative images from Fig. 4a as well 
as 53BP1 and gH2AX controls showing DNA damage foci was present across all cell lines. Scale bar is 10 µm. (c) 
Cartoon of modified DR-GFP assay. In order to exclude the difference caused by transfection efficiency 
between the cell lines, we replaced the puromycin cassette with BFP5.  The plasmid was pre-cut by I-SceI and 
transfected into cells followed by flow cytometry. The HR efficiency was defined as the percentage of GFP 
positive cells in BFP positive population. (d) Representative flow cytometry graphs showing BFP and GFP status 
as well the mean ± S.D. of n = 3 biological replicates gated. See Fig. 4b. (e) Representative images from Fig. 4d. 
Scale bar is 10 µm. (f) Cell cycle distributions of cells from siRNA treatments described in Fig. 4c-e. Changes in 
RAD51 foci resulting from BRCA1 siRNA treatment were not a result of diminished S/G2/M phase cells. Data 





Supplementary Figure 4. Characterization of BRCA1 intron-containing proteins. 
(a) MDA-MB-436 cells engineered to express HA-BRCA1 c.5445G>A and SNU-251 cells were treated with 
MG132 for 0, 6, and 12 hours and ectopic HA or endogenous BRCA1 assessed by Western blotting. MG132 
resulted in marked increase in ectopic c.5445G>A HA-BRCA1 protein levels in MDA-MB-436 cells. Similarly, 
when SNU-251 cells were treated with MG132, we observed a BRCA1 protein band migrating above the intron 
15 containing isoform, potentially the BRCA1 c.5445G>A associated protein product that is 1814 aa in length. 
However, we were unable to immunoprecipitate enough protein to confirm this by mass spectrometry. Thus, 
BRCA1 BRCT domain mutations, including the mutation present in SNU-251 cells, induce proteasomal 
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degradation, likely resulting from protein folding defects. (b) Cartoon of full-length BRCA1 showing functional 
domains relative to BRCA1-intron 14 and BRCA1-intron 15 generated stop codons and protein isoforms. 
BRCA1 amino acid sequences generated from intron 14 and intron 15 through to intron-induced stop codons 
are depicted. Intron 14 codes for an immediate stop codon after exon 14. Intron 15 codes for 12 amino acids 
followed by a stop codon. (c) Representative images and HA, RAD51, g-H2AX and 53BP1 foci from MDA-MB-
436 cells expressing the indicated constructs in the presence or absence of IR. mCherry (mCh), Full-length (FL), 





Supplementary Figure 5. Proteomic and WGS analyses of BRCA1 in PDX tumors. 
(a) BRCA1 was immunoprecipitated from PDX221 lysates and subject to mass spectrometric analyses as 
described in Fig. 1. The identical BRCA1-I15 peptide identified in SNU-251-RR cells was also found in PDX221. 
(b) IGV of reads that mapped to both chromosome 17 and 21 regions where breakpoints are located in 
PDX221; and chromosome 17 and 22 where breakpoints are located in PDX418. Red line indicates breakpoints, 
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gray bars on y axis correspond to the number of reads detected on the particular chromosome location. (c) 
View of individual reads detected in PDX221 are shown that mapped to both chromosome 17 and 21; as well 
as individual reads detected in PDX418 that mapped to both chromosome 17 and 22. Green box highlights the 
single split reads. (d) The t(17;21)(q21.31;q22.3) and t(17;22)(q21.31;q23.1) translocation junctions in PDX221 





















Supplementary Table 1. Cell line information. 
Cell line Disease BRCA1 (HGVS) BRCA2 (HGVS) 
MDA-MB-231 TNBC WT  WT 
SNU-251 OvCa c.5445G>A  WT  
MDA-MB-436 TNBC c.5277+1G>A  WT 
 
TNBC – triple negative breast cancer; OvCa – ovarian cancer. Of note, the BRCA1 wild-type allele was 
undetectable in SNU-251 and MDA-MB-436 cells. See BROCA appendix table in Supplementary Data 2 file for 
more information. 
 
Supplementary Table 2. PDX information. 
PDX Disease 
BRCA1 
(HGVS) Protein predicted Therapies prior to establishing PDX  
PDX 
Olaparib 
221 TNBC c.5027delT p.Leu1676* 1. NeoAdj doxorubicin + cyclophosphamide + 5FU → paclitaxel 
PD 
 
236 TNBC c.5194-12G>A p.His1732Phefs*5 
1. NeoAdj doxorubicin + cyclophosphamide + 
docetaxel; 2. paclitaxel + gemcitabine; 
3. capecitabine;  4. pegylated irinotecan 
PD 
 
252 TNBC c.5123C>A p.Ala1708Glu 
1. NeoAdj epirubicin + docetaxel; 2. 
carboplatin + gemcitabine; 
3. lurbinectedin (PM01183) 
PD 
 
397 OvCa c.5108A>C p.Tyr1703Ser 1. carboplatin + paclitaxel;  2. carboplatin + pegylated liposomal doxorubicin; 
PD 
 
418 ER+BC c.5266dupC p.Gln1756Profs*74 
1. paclitaxel + gemcitabine; 2. talazoparib; 3. carboplatin 
+ gemcitabine → carboplatin; 4. capecitabine; 5. eribulin; 




PD – progressive disease/growth is similar to vehicle treated tumors 







Supplementary Table 3. Primer sequences 
RT-PCR primers for detecting Wild-type and I15 BRCA1 isoforms 
BRCA1 exon11 F GATGATGGTGAAATAAAGGAAGATACTA 
BRCA1 exon24 R GATCTGGGGTATCAGGTAGGTGTC 
BRCA1 intron15 R ATCTTGGCTCACCGCAACC 
 
qRT-PCR primers for detecting Wild-type and I15 BRCA1 isoforms 
BRCA1 exon2/3 F TTATCTGCTCTTCGCGTTGAAG 
BRCA1 exon2/3 R TTGTGGAGACAGGTTCCTTGAT 
BRCA1 exon15/intron15 F ATTAAGGTTGTTGATGTGGAGGAG 
BRCA1 exon15/intron15 R AGTGTTTGTTCCAATACAGCAGATG 
BRCA1 exon15/16 F GAATAGAAACTACCCATCTCAAGAGGA 
BRCA1 exon15/16 R CAGGTAAGGGGTTCCCTCTAGAT 
BRCA1 exon18/19 F AAATATTTTCTAGGAATTGCGGGA  
BRCA1 exon18/19 R TCTTTCTTTAATAGACTGGGTCACCC 
RPLP0 F CCCATTCTATCATCAACGGGTACAA  
RPLP0 R CAGCAAGTGGGAAGGTGTAATCC 
HA F CCTACGACGTGCCCGACTA  
BRCA1 exon2 (used for HA) R ATGGGACACTCTAAGATTTTCTGCA 
 
Primers used to detect the mutations in exon 23 and exon 15/intron 15 
BRCA1 intron22 F AGGTGTGAGCATCGCTTGAAC  
BRCA1 intron23 R CCCACAGCCTCTGGCAACT 
BRCA1 intron14 F ACAGGGCTGTATAGCAGTCCAGTA  
BRCA1 intron15 R GGCATGAGCAGTGGCTGTAAT 
  
Primers used in 3’RACE 
oligo dT with adapter GAGGACTCGAGCTCAAGCCGCGTCGACTAGTAC(T)18 
1st Round F (BRCA1 exon 13) ACTCAGCAGAGGGATACCAT  
1st Round R GAGGACTCGAGCTCAAGC 
2nd Round F (BRCA1 exon 15) CACAGTTGCTCTGGGAGTCTTC 
2nd Round R AGCCGCGTCGACTAGTAC 
 

















Primers used to make I14, I15 BRCA1 cDNA 
BRCA1 intron13 F TTTCATGTCTGACACTCATGTCTTG 
BRCA1 intron14 R GGAGGCTAAGGTGGGAGGAT 
BRCA1 exon11 F GATGATGGTGAAATAAAGGAAGATACTA 
























SUPPLEMENTARY NOTE 1. gDNA sequences  
 
gDNA sequence at BRCA1 locus breakpoints in SNU251-RR Cells 
Uppercase: BRCA1 Exon15 (chr17) 
Lowercase: BRCA1 intron15 (chr17) 
Alu element 
Uppercase: reversed insertion of BRCA1 Exon15 (chr17) 
Lowercase: reversed insertion of intron15 (chr17) 
Alu element 
Lowercase: reversed insertion of NBR2 intron1 (chr17) 
Alu element 
random insertion 

















































































gDNA sequence at BRCA1 locus breakpoint in PDX221 
Uppercase: BRCA1 Exon15 (chr17) 
Lowercase: BRCA1 intron15 (chr17) 
Alu element 
Lowercase: non-coding region (chr21) 
MLT1B element 



















































gDNA sequence at BRCA1 locus breakpoint in PDX418  
Uppercase: BRCA1 Exon15 (chr17) 
Lowercase: BRCA1 intron15 (chr17) 
Alu element 
Lowercase: CBX6 intron4 (chr22) 
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